DE69720283T2 - Bestimmung der krebsanfälligkeit eines organs oder gewebes durch bestimmung seiner zellprägung - Google Patents

Bestimmung der krebsanfälligkeit eines organs oder gewebes durch bestimmung seiner zellprägung Download PDF

Info

Publication number
DE69720283T2
DE69720283T2 DE69720283T DE69720283T DE69720283T2 DE 69720283 T2 DE69720283 T2 DE 69720283T2 DE 69720283 T DE69720283 T DE 69720283T DE 69720283 T DE69720283 T DE 69720283T DE 69720283 T2 DE69720283 T2 DE 69720283T2
Authority
DE
Germany
Prior art keywords
imprinting
methods
restoring
normal
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69720283T
Other languages
English (en)
Other versions
DE69720283D1 (de
Inventor
Andrew P Feinberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
School of Medicine of Johns Hopkins University
Original Assignee
Johns Hopkins University
School of Medicine of Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University, School of Medicine of Johns Hopkins University filed Critical Johns Hopkins University
Application granted granted Critical
Publication of DE69720283D1 publication Critical patent/DE69720283D1/de
Publication of DE69720283T2 publication Critical patent/DE69720283T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
DE69720283T 1996-12-30 1997-12-29 Bestimmung der krebsanfälligkeit eines organs oder gewebes durch bestimmung seiner zellprägung Expired - Lifetime DE69720283T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3409596P 1996-12-30 1996-12-30
PCT/US1997/023991 WO1998029108A2 (en) 1996-12-30 1997-12-29 Compositions and methods for restoring a normal pattern of imprinting to cells

Publications (2)

Publication Number Publication Date
DE69720283D1 DE69720283D1 (de) 2003-04-30
DE69720283T2 true DE69720283T2 (de) 2004-01-29

Family

ID=21874277

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69720283T Expired - Lifetime DE69720283T2 (de) 1996-12-30 1997-12-29 Bestimmung der krebsanfälligkeit eines organs oder gewebes durch bestimmung seiner zellprägung

Country Status (9)

Country Link
EP (1) EP0969822B1 (de)
JP (2) JP4913270B2 (de)
AT (1) ATE235190T1 (de)
AU (1) AU5722398A (de)
CA (1) CA2276306C (de)
DE (1) DE69720283T2 (de)
DK (1) DK0969822T3 (de)
ES (1) ES2195196T3 (de)
WO (1) WO1998029108A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6803195B1 (en) * 1999-07-02 2004-10-12 Ramot At Tel-Aviv University Ltd. Facile detection of cancer and cancer risk based on level of coordination between alleles
GB0107267D0 (en) * 2001-03-23 2001-05-16 Babraham Inst Diagnostic method for determining the methylation state of cloned embryos
US6982253B2 (en) 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
AU2002952944A0 (en) * 2002-11-27 2002-12-12 Human Genetic Signatures Pty Ltd Restoration of methylation states in cells
US7799525B2 (en) 2003-06-17 2010-09-21 Human Genetic Signatures Pty Ltd. Methods for genome amplification
WO2005024053A1 (en) 2003-09-04 2005-03-17 Human Genetic Signatures Pty Ltd Nucleic acid detection assay
US8168777B2 (en) 2004-04-29 2012-05-01 Human Genetic Signatures Pty. Ltd. Bisulphite reagent treatment of nucleic acid
WO2006026828A1 (en) 2004-09-10 2006-03-16 Human Genetic Signatures Pty Ltd Amplification blocker comprising intercalating nucleic acids (tna) containing intercalating pseudonucleotides (ipn)
NZ555620A (en) 2004-12-03 2008-08-29 Human Genetic Signatures Pty Methods for simplifying microbial nucleic acids by chemical modification of cytosines
AU2006251866B2 (en) 2005-05-26 2007-11-29 Human Genetic Signatures Pty Ltd Isothermal strand displacement amplification using primers containing a non-regular base
US8343738B2 (en) 2005-09-14 2013-01-01 Human Genetic Signatures Pty. Ltd. Assay for screening for potential cervical cancer
GB0607063D0 (en) 2006-04-07 2006-05-17 Cellcentric Ltd Compositions and methods for epigenetic modification of nucleic acid sequences in vivo
EP2215250B1 (de) 2007-11-27 2013-02-27 Human Genetic Signatures Pty Ltd Enzyme zur amplifikation und zum kopieren bisulphit-modifizierter nukleinsäuren
CN103874766B (zh) 2011-09-07 2017-07-18 人类遗传标记控股有限公司 分子检测测定
WO2018214249A1 (zh) 2017-05-22 2018-11-29 立森印迹诊断技术（无锡）有限公司 一种印记基因分级模型及其组成的系统和应用
CN112313345B (zh) * 2018-05-18 2024-02-20 立森印迹诊断技术（无锡）有限公司 一种通过活检细胞样本诊断癌症的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58177949A (ja) * 1982-04-12 1983-10-18 Takeda Chem Ind Ltd ランカシジン群抗生物質包接化合物
JPS61176523A (ja) * 1985-01-30 1986-08-08 Teruhiko Beppu 制癌剤
EP0631584A4 (de) * 1991-02-28 1998-07-01 Dana Farber Cancer Inst Inc Krebs diagnose und therapie.
EP0627436A1 (de) * 1991-08-08 1994-12-07 TSUMURA & CO. Carcinostatische verbindungen und ihre herstellung
US5356903A (en) * 1993-04-22 1994-10-18 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolines

Also Published As

Publication number Publication date
JP2009072197A (ja) 2009-04-09
CA2276306C (en) 2009-12-15
EP0969822B1 (de) 2003-03-26
EP0969822A2 (de) 2000-01-12
ATE235190T1 (de) 2003-04-15
WO1998029108A3 (en) 1999-02-18
DK0969822T3 (da) 2003-07-21
DE69720283D1 (de) 2003-04-30
WO1998029108A2 (en) 1998-07-09
AU5722398A (en) 1998-07-31
JP2001507703A (ja) 2001-06-12
ES2195196T3 (es) 2003-12-01
CA2276306A1 (en) 1998-07-09
JP4913270B2 (ja) 2012-04-11

Similar Documents

Publication Publication Date Title
DE69720283D1 (de) Bestimmung der krebsanfälligkeit eines organs oder gewebes durch bestimmung seiner zellprägung
Tasmuth et al. Chronic post-treatment symptoms in patients with breast cancer operated in different surgical units
Salman et al. Actinic lichen planus: a clinicopathologic study of 16 patients
DE69725293D1 (de) N-(2 oxoacetyl oder sulphonyl)-pyrrolidine/piperidine-2-carbonsäurederivate mit verbesserter multi-drug resistenz aktivität
HUP0302549A2 (hu) Eritropoietin-érzékeny sejtek, szövetek és szervek védelme, helyreállítása és növelése
ATE173155T1 (de) Mittel zur künstlichen bräunung mit verbesserter stabilität
ES2123714T3 (es) Aislamiento y estructura de las esponjistatinas 5,7,8 y 9 y su empleo como agentes antitumorales.
HK1074486A1 (en) Oxaliplatin anti-resistance method
Frenk et al. Neurofibromatosis of von Recklinghausen: a quantitative study of the epidermal keratinocyte and melanocyte populations
Lumerman et al. Intraoral (submucosal) pseudosarcomatous nodular fasciitis: report of a case
Kanerva et al. Hyperpigmentation and Hypopigmentation of the Skin after Long Term PUVA Therapy: Light and electron microscopic observations on three patients
WO1999045103A3 (en) Human spinal cord cell lines and methods of use therefor
EP1332756A3 (de) Zusammensetzungen und Methoden zur Wiederherstellung einer normalen Zellprägung
BR9607178A (pt) Antagonista de peptìdeo de hormÈnio estimulando alfa -melanócitos, processos para a inibição da atividade de hormÈnio estimulando alfa-melanócitos em um tecido ou célula que responde a hormÈnio estimulando alfa -melanócitos, para o clareamento da complexação de um animal e para o tratamento de melanoma maligno, composição farmacêutica, e, kit
LEVIN A specific skin lesion in gargoylism
TR199801359T2 (xx) H�cre b�y�mesini engellemek i�in kalsiyum kanal blokeri olan terkipler
Cole Chronic roentgen-ray dermatoses as seen in the professional man
Mohammed et al. Histopathological study of malignant melanoma in highlanders
Walker et al. Nasolabial flap reconstruction for carcinoma of the lower lip: An eleven year follow-up study
Barthelmes et al. An audit of the management of emergency surgical admissions in Wales: are we keeping pace with the trend?
WO2004019875A3 (en) Non-invasive methods to identify agents for treating pain
Tsao et al. Governance of Cutaneous Photocarcinogenesis by Chronic UVA-Exposed Dermal Fibroblasts
Brolsma Precancerous dermatoses
Haug Issues and controversies in the management of cleft palate: Nguyen PN, Sullivan PK. Clin Plast Surg 20: 671, 1993
Ebert CHICAGO DERMATOLOGICAL SOCIETY

Legal Events

Date Code Title Description
8364 No opposition during term of opposition